Immunocore Holdings plc

Greetings. Welcome to the Immunocore Fourth Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. The question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to Clayton Robertson, Head of Investor Relations. Thank you. You may begin.

Thank you, Daryl. Welcome everyone to our Q4 and full year 2023 financial results call. Before we begin, I would like to remind you that this call will contain forward-looking statements within the meaning of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. These include expectations and plans concerning future events, prospects, and performance, including with respect to commercialization, clinical development and trials, regulatory approvals, and financial results. Actual events may differ materially from those indicated by these four looking statements as a result of various important factors, including those disclosed in our filings with the SEC. And such statements represent our views only as of the date of this webcast and should not be replied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update such statements. With that, I'm now pleased to introduce Immunicare CEO, Dr. Fadija Jalal.

Thank you, Clay. Hello, everyone. With me today are Rob Torbay, our head of commercial, David Berman, our head of R&D, and Brian DiDonato, our chief financial officer. We will be happy to take your questions at the end. At Immunocore, we are driven by a clear mission to bring transformative immunomodulating medicines to patients. In 2023, we continue to advance our three strategic pillars of maximizing the potential of ChemTrack, advancing our clinical portfolio, and continuing to innovate for sustainable growth. Let's look at the first one. On ChemTrack, last year, we achieved 239 million in net ChemTrack sales. Going into 2024, we see three growth opportunities. First, continuous commercial growth driven by the US. Second, mid-term growth driven by Q4 data from TEBI-AM trial. And third, long-term growth with the ATOM trial expected to start recruiting this year. The second pillar on the portfolio. We continue to advance our clinical portfolio With the announcement of our first PRAME phase three trial in first line advanced cutaneous melanoma, we intend to randomize the first patient in Q1. PRAME clinical data updates in melanoma, ovarian, and lungs will come throughout 2024. Reflecting our enthusiasm for the PRAME targets, we are advancing two new candidates into the clinic this year. In December, we submitted the CTA for a first-year class candidate targeting P. will in colorectal and GI cancers. And we continue to pursue a potential functional cure in HIV with phase one beta for the first half or second half of 2024. The third pillar is an innovation. In last month, we announced that we had added two novel tissue-targeted autoimmune programs one for type 1 diabetes and the second for dermatology indications. You will hear more about each of these exciting programs from David. These additions expand the therapeutic areas we aim to treat to three. And now I'm happy to hand over to Ralf to share more information about KimTrack. Ralf?